Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
Tsutsumi
Yutaka
Y
Kanamori
Hiroe
H
Yamato
Hiroaki
H
Ehira
Nobuyuki
N
Miura
Takuya
T
Kawamura
Takahito
T
Obara
Shinji
S
Tanaka
Junji
J
Asaka
Masahiro
M
Imamura
Masahiro
M
Masauzi
Nobuo
N
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood*; D001549:Benzamides; D001827:Body Height; D001835:Body Weight; D004305:Dose-Response Relationship, Drug; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000097:blood*; D011743:Pyrimidines / Q000008:administration & dosage / Q000097:blood*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate